{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"97.5","value":"88.0"}]}],"title":"by cycle 66"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG000","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"6, 12, 18, 24, 36, 48, 66 cycles","title":"Best Major Cytogenetic Response (MCyR) Rate by Time Point in Newly Diagnosed Ph+ CML Patients","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}